Two non-psychoactive cannabinoids reduce intracellular lipid levels and inhibit hepatosteatosis.

.

Significance :

The significance of this study lies in exploration of potential therapeutic agents for non-alcoholic

fatty liver disease (NAFLD) and metabolic syndrome, that are increasingly prevalent due to

rising obesity rates. The study investigates the effects of cannabinoids, specifically THCV

and CBD, for their potential to improve insulin sensitivity and lipid metabolism. This could

lead to new pharmacological treatments for NAFLD, as effective therapies.

.

Importance of lipidology :

The effects of THCV and CBD on lipid levels were examined in a variety of in vitro and in vivo

systems, with special emphasis on models of hepatosteatosis. Treatment also induced

post-translational changes in a variety of proteins such as CREB, PRAS40, AMPKa2 and

several STATs indicating increased lipid metabolism and, possibly, mitochondrial activity.

They show here that both THCV and CBD reduce intracellular lipid levels in vitro in a model

of hepatosteatosis and adipocytes, mobilize zebrafish embryo lipid yolk stores and inhibit

hepatosteatosis in obese mice.

.

Connectivity to other fields :

The implications of this study consist of various fields beyond hepatology and metabolic

research, including pharmacology, nutrition, and mental health. This highlights the

interdisciplinary nature of metabolic research.

-

READ MORE

https://pubmed.ncbi.nlm.nih.gov/25595882/